<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03402828</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-PSORIASIS-1379</org_study_id>
    <nct_id>NCT03402828</nct_id>
  </id_info>
  <brief_title>Body PSOriasis: Long-term Relapse CONTROL</brief_title>
  <acronym>PSO-CONTROL</acronym>
  <official_title>Body PSOriasis: Long-term Relapse Control in Patients With Psoriasis Vulgaris in Daily Clinical Practice of Russian Dermatologists.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This non-interventional study of real-life clinical practice strategies for long-term relapse
      control in patients with psoriasis vulgaris is planned to enroll 650 adult patients from
      60-100 Russian dermatology sites and follow the patients for up to 52 weeks. The study will
      map actual strategies and focus on patients' and dermatologists' experience with the
      different topicals used, including unspecified products with and without active drugs.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2018</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time of relapse</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>Length of relapse free period after start of maintenance strategy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dermatology Life Quality Index</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>Standard QoL measure within dermatology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PGA (physician's global assessment of symptoms)</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>5-point verbal rating scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PsGA (patient's global assessment of symptoms)</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>5-point verbal rating scale</description>
  </secondary_outcome>
  <enrollment type="Anticipated">650</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Any topical drug treatment</intervention_name>
    <description>Any treatment strategy used to prevent relapse of psoriasis symptoms</description>
    <other_name>Non-drug topicals</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with psoriasis vulgaris attending one of the participating outpatient dermatology
        clinics entering a phase of prevention of relapse of psoriasis symptoms.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients planned to receive topical treatment of any kind to prevent relapse of
             symptoms

          -  Written informed consent

        Exclusion Criteria:

          -  Contraindications to selected treatment

          -  Ongoing systemic treatment of psoriasis with steroids, anti-inflammatory drugs or
             phototherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dmitry Petrunin, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Leo Pharmaceutical Products LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dmitry Petrunin, MD PhD</last_name>
    <phone>+74957891160</phone>
    <email>DYPRU@leo-pharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The State Autonomous Foundation of Public Health &quot;Republic Clinical Dermatovenereological Dispensary&quot; of the Republic of Tatarstan</name>
      <address>
        <city>Kazan</city>
        <state>Tatarstan</state>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2018</study_first_submitted>
  <study_first_submitted_qc>January 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2018</study_first_posted>
  <last_update_submitted>January 11, 2018</last_update_submitted>
  <last_update_submitted_qc>January 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Topicals</keyword>
  <keyword>Long-term</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

